Defensine: körpereigene Antibiotika als zentraler Bestandteil des angeborenen Immunsystems

Schlüsselwörter

Defensine - chronische entzündliche Darmerkrankungen - Morbus Crohn

Key words

defensins - inflammatory bowel disease - CrohnŽs disease

Literatur

• 1 Ayabe T, Satchell D P. et al . Secretion of microbicidal alpha-defensins by intestinal paneth cell response to bacteria.  Nat Immunol. 2000;  1 113-118
• 2 Bals R. Roles of antimicrobial peptides in pulmonary disease. In Devine DA, Hancock RE (eds): Mammalian Host Defense Peptides Cambridge University Press, Cambridge 2004: 349-374
• 3 Bals R, Hiemstra P S. Innate immunity in the lung: How epithelial cells fight against respiratory pathogens.  Europ Resp J. 2004;  23 327-333
• 4 Bevins C L. The paneth cell and the innate immune response.  Current Opin Gastroenterol. 2004;  20 572-580
• 5 Darfeuille-Michaud A, Boudeau J, Bulois P. et al . High prevalence of adherent-invasive escherichia coli associated with ileal mucosa in Crohn’s disease.  Gastroenterology. 2004;  127 412-421
• 6 Duchmann R, May E, Heike M. et al . T cell specifity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans.  Gut. 1999;  44 812-818
• 7 Fellermann K, Stange D E. et al . A chromosome 8 gene cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to CrohnŽs disease of the colon.  Am J Hum Genet. 2006;  (in press)
• 8 Gaya D R. et al . New genes in inflammatory bowel disease: lessons for complex diseases?.  Lancet. 2006;  367 1271-1284
• 9 Harder J, Bartels J, Christophers E, Schröder J M. A peptide antibiotic from human skin.  Nature. 1997;  387 861
• 10 Harder J, Bartels J, Christophers E, Schröder J M. Isolation and characterization of human B-defensin-3, a novel human inducible peptide antibiotic.  J Biol Chem. 2001;  276 5707-5713
• 11 Hu R C, Xu Y J, Zhang Z X, Ni W, Chen S X. Correlation of HDEFB1 Polymorphism and susceptibility to chronic obstructive pulmonary disease in Chinese Han population.  Chin Med J (Engl ). 2004;  117 1637-1641
• 12 Kobayashi K S. et al . Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.  Science. 2005;  307 731-734
• 13 Kruis W, Fric P, Pokrotnieks J. et al . Maintaining remission of ulcerative colitis with the probiotic escherichia coli Nissle 1917 is as effective as with standard mesalazine.  Gut. 2004;  53 1617-1623
• 14 Lala S, Ogura Y, Osborne C. et al . Crohn’s disease and the NOD2 gene: a role for paneth cells.  Gastroenterology. 2003;  125 47-57
• 15 Lehrer R I, Bevins C L. Defensins and other antimicrobial peptides. New York, Academic Press In: Mestecky J, Bienenstock J., Lammet M E, Strober W et al. (eds) Mucosal Immunology 2004: 95-110
• 16 Matsushita I, Hasegawa K, Nakata K, Yasuda K, Tokunaga K, Keicho N. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease.  Biochem Biophys Res Commun. 2002;  291 17-22
• 17 Ong P Y, Ohtake T, Brandt C. et al . Endogenous antimicrobial peptides and skin infections in atopic dermatitis.  N Engl J Med. 2002;  347 1151-1160
• 18 Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment.  Cell Mol Life Sci. 2005;  62 784-790
• 19 Peschel A. How do bacteria resist human antimicrobial peptides?.  Trends Microbiol. 2002;  10 179-186
• 20 Salzman N H, Chou M M, de Jong H, Liu L, Porter E M, Paterson Y. Enteric salmonella infection inhibits paneth cell antimicrobial peptide expression.  Infect Immun. 2003;  71 1109-1115
• 21 Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K, Scheppach W, Gallo R L, Stange E F. Heterogeneous expression of human cathelicidin HCAP18/LL-37 in inflammatory bowel diseases.  Eur J Gastroenterol Hepatol. 2006;  18 615-621
• 22 Schröder J M, Harder J. Antimicrobial skin peptides and proteins.  Cell Mol Life Sci. 2006;  63 469-486
• 23 Swidsinski A, Ladhoff A, Pernthaler A. et al . Mucosal flora in inflammatory bowel disease.  Gastroenterology. 2002;  122 44-54
• 24 Wehkamp J, Fellermann K, Herrlinger K, Bevins C, Stange E F. Mechanisms of disease: defensins in gastrointestinal diseases.  Nature Clin Pract. 2005;  2 406-415
• 25 Wehkamp J, Fellermann K. et al . Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.  Eur J Gastroenterol Hepatol. 2002;  14 745-752
• 26 Wehkamp J, Harder J, Wehkamp K. et al . NF-KB and AP-1 mediated induction of human beta defensin-2 in intestinal epithelial cells by E. Coli Nissle 1917: a novel effect of a probiotic bacterium .  Infect Immun. 2004;  72 5750-5758
• 27 Wehkamp J, Harder J, Weichenthal M, Mueller O. et al . Inducible and Constitutive Beta-Defensins Are Differentially Expressed in Crohn’s Disease and Ulcerative Colitis.  Inflamm Bowel Dis. 2003;  9 215-223
• 28 Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaeffeler E, Schlee M. et al . NOD2 (CARD15) Mutations in CrohnŽs disease are associated with diminished mucosal a-dexpression.  Gut. 2004;  53 1658-1664
• 29 Wehkamp J, Salzman N H, Porter E. et al . Reduced paneth cell {Alpha}-defensins in ileal Crohn’s disease.  PNAS. 2005;  102 18129-18134
• 30 Wehkamp J, Schmid M, Fellermann K, Stange E F. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn’s d.  J Leukoc Biol. 2005;  77 460-465
• 31 Whitsett J A. Intrinsic and innate defenses in the lung: Intersection of pathways regulating lung morphogenesis, host defense, repair.  J Clin Invest. 2002;  109 565-569